Member Exclusive News

The week in industry: Global rights for brain cancer drug acquired by CNS Pharmaceuticals

This week: First targeted therapy for a sickle cell disease complication approved, collaboration announced to extended to advance cancer therapy development and grant awarded for the development of novel idiopathic pulmonary fibrosis therapeutics.

Go to the profile of RxNet
Nov 21, 2019
0
0

Please sign in or register for FREE

No comments yet.